Company news

Aura Biosciences, Inc. news in 2023

Aura Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

December 6, 2023

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

November 8, 2023

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

November 5, 2023

Aura Biosciences Announces Proposed Public Offering of Common Stock

November 5, 2023

Aura Biosciences Announces Pricing of Public Offering of Common Stock

November 5, 2023

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

October 30, 2023

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

October 1, 2023

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

August 8, 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 11, 2023

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 10, 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

March 14, 2023

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

February 15, 2023

Decks in 2023